Affiliation: Baylor College of Medicine
- Delayed-onset heparin-induced thrombocytopeniaLawrence Rice
Baylor College of Medicine, The Methodist Hospital, and St Luke's Episcopal Hospital, 6565 Fannin Street, MS 902-Main, Suite 930, Houston, TX 77030, USA
Ann Intern Med 136:210-5. 2002..To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated...
- Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospitalSandeep Kodityal
Baylor College of Medicine, Houston, TX, USA
J Intensive Care Med 21:86-92. 2006..In contemporary "real world" use, argatroban provides safe and effective anticoagulation, strengthening the mandate to initiate alternative anticoagulation whenever heparin-induced thrombocytopenia appears likely...
- Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopeniaLawrence Rice
The Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA
J Clin Pharmacol 47:1028-34. 2007
- The role of beta-catenin in chronic myeloproliferative disordersMonica P Jauregui
Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
Hum Pathol 39:1454-8. 2008..In addition, beta-catenin may be a useful marker for differentiating polycythemia vera and essential thrombocythemia from other types of chronic myeloproliferative disorders...
- Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient)Lawrence Rice
Section of Hematology/Oncology, Baylor College of Medicine, 6565 Fannin St, MS 902, Room 930, Houston, TX 77030, USA
Arch Intern Med 164:1961-4. 2004
- Drug evaluation: AMG-531 for the treatment of thrombocytopeniasLawrence Rice
Baylor College of Medicine, Houston, TX 77030, USA
Curr Opin Investig Drugs 7:834-41. 2006..A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France...
- Every case of essential thrombocythemia should be tested for the Philadelphia chromosomeLawrence Rice
Department of Medicine, Hematology Oncology Section, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Am J Hematol 78:71-3. 2005..We conclude that CML can present in identical fashion as ET. The mandate for routine Philadelphia chromosome testing is magnified by the availability of targeted therapy and its greater efficacy in early stage disease...
- Cases of heparin-induced thrombocytopenia elucidate the syndromeLawrence Rice
Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS 902, Room 930, Houston, TX 77030, USA
Chest 127:21S-6S. 2005..The potential beneficial impact of therapy with direct thrombin inhibitors makes it more important to maintain awareness of and vigilance for this syndrome...
- Current management of the myeloproliferative disorders: a case-based reviewLawrence Rice
Department of Medicine Hematology Oncology Section, Baylor College of Medicine, Houston, Tex 77030, USA
Arch Pathol Lab Med 130:1151-6. 2006..The cytoreductive agent of choice for these disorders is currently hydroxyurea, emerging from randomized trials beginning with those of the Polycythemia Vera Study Group...
- The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestationsLawrence Rice
Hematology Oncology Section, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Cell Physiol Biochem 15:245-50. 2005..Ongoing studies to identify the molecular targets and cytokine intermediaries should facilitate detection, dissection and eventual therapeutic manipulation of the process...
- Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomesLawrence Rice
Baylor College of Medicine, 6565 Fannin, MS 902, Houston, TX 77030, USA
Postgrad Med 112:85-9. 2002..Use of alternative anticoagulants is improving patient outcomes. Lepirudin, argatroban, and danaparoid each have advantages and disadvantages; treatment should be tailored to each patient...
- Evolving management strategies for heparin-induced thrombocytopeniaLawrence Rice
Baylor College of Medicine, Texas Medical Center, Houston, TX, USA
Semin Hematol 42:S15-21. 2005..Because of its favorable pharmacologic characteristics, the DTI bivalirudin has been successfully employed in HIT, particularly in patients with multiorgan failure...
- Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell massL Rice
Section of Hematology, Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS 902 Main, Houston, TX 77030, USA
Ann Intern Med 134:652-6. 2001..Studies of space-flight anemia have uncovered a physiologic process, neocytolysis, by which young red blood cells are selectively hemolyzed, allowing rapid adaptation when red cell mass is excessive for a new environment...
- Modulation of red cell mass by neocytolysis in space and on EarthL Rice
Section of Hematology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Pflugers Arch 441:R91-4. 2000..Thus, unraveling a problem for space travelers has uncovered a physiologic process controlling the red cell mass that can be applied to human disorders on Earth...
- Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failuresSandeep Kodityal
The Department of Medicine, Section of Hematology, Baylor College of Medicine, Houston, TX, USA
Eur J Haematol 71:109-13. 2003..The latter problem probably extrapolates to other anticoagulants used for HIT...
- Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibitionJianguo Wen
Department of Pathology, The Methodist Hospital and Research Institute, Houston, TX 77030, USA
Leuk Res 34:85-92. 2010..The results suggest the opportunity for using p38 MAPK inhibition to enhance the efficacy of ATO+bortezomib in myeloma...
- Heparin-induced thrombocytopenia in the cardiac patient: 10 points to help the physicianLawrence Rice
Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, Texas, USA
Methodist Debakey Cardiovasc J 7:6-9. 2011..The patient demanded transfer to our hospital. His subsequent course was benign, including transition to warfarin and discontinuation of anticoagulants after 6 months...
- Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopeniaMartha P Mims
Department of Medicine, Section of Hematology-Oncology, Baylor College of Medicine, 6565 Fannin, Houston, TX 77030, USA
Eur J Haematol 72:366-9. 2004..Appreciation of this phenomenon can unmask cases of heparin-induced thrombocytopenia and strengthens the mandate to avoid any heparin exposure in affected patients. Recognition is crucial to avoiding disastrous outcomes...
- p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromesMunir Shahjahan
Department of Pathology, Methodist Hospital and Methodist Research Institute, Houston, TX, USA
Am J Clin Pathol 130:635-41. 2008..007) cases. Increased p38 MAPK activation may have a role in inhibiting hematopoiesis leading to cytopenias in MDS, and relatively decreased p38 activation in MPD might promote hematopoiesis, resulting in cytosis...
- Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopeniaAbhay F Srinivasan
Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex. 77030, USA
Arch Intern Med 164:66-70. 2004..Warfarin should be initiated at modest doses in patients with HIT after platelet recovery. Implications extend to warfarin initiation with other thrombotic diatheses...
- Introduction. What's happening with heparin-induced thrombocytopenia: emerging preventive, diagnostic, and management strategiesLawrence Rice
Baylor College of Medicine, Texas Medical Center, USA
Semin Hematol 42:S1-2. 2005
- Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis studyArsalan Ahmed
The Department of Pathology and Laboratory Medicine, The Methodist Hospital and Research Institute, Houston, TX 77030, USA
Pathol Res Pract 205:634-8. 2009..Further studies are warranted to confirm our observation and to study the mechanisms by which mast cells contribute to fibrosis in the MPN setting...
- Necrobiotic xanthogranuloma with posterior scleritisKirk R Wilhelmus
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, 6565 Fannin Street, Houston, TX 77030, USA
Arch Ophthalmol 124:748. 2006
- Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interfaceJ Trial
Department of Medicine, Baylor College of Medicine and the Veterans Affairs Medical Center, Houston, Texas 77030 4211, USA
Curr Pharm Des 10:183-90. 2004..New erythropoietin products and methods of administration avoid the intermittent rapid decreases associated with the stimulus for neocytolysis, but study of this phenomenon may yield further improvements in drug design...
- Neocytolysis contributes to the anemia of renal diseaseL Rice
Methodist Hospital, Houston, TX, USA
Am J Kidney Dis 33:59-62. 1999..One implication is the prediction that intravenous bolus EPO therapy is metabolically and economically inefficient compared with lower doses administered more frequently subcutaneously...
- Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysisJ Trial
Department of Medicine, Baylor College of Medicine, and Veterans Affairs Medical Center, Houston, Tex 77030 4211, USA
J Investig Med 49:335-45. 2001....
- The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosisRandall J Olsen
Department of Pathology and Laboratory Medicine, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX, USA
J Hematop 1:111-7. 2008..Our results suggest that JAK2 ( V617F ) allele evaluation can be a useful ancillary test for discriminating MDS from MPN in specimens with bone marrow fibrosis...
- Laparoscopic splenectomy for chronic recurrent thrombotic thrombocytopenic purpuraFrancis A Essien
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Surg Laparosc Endosc Percutan Tech 13:218-21. 2003..The inherent benefits of the minimally invasive approach, its low morbidity, short hospital stay, and faster recovery, are significant advantages for these patients...
- Unusual autoimmune nonhematologic complications in chronic lymphocytic leukemiaMoonjung Jung
Department of Medicine, The Methodist Hospital, Weill Cornell Medical College, Houston, TX 77030, USA
Clin Lymphoma Myeloma Leuk 11:S10-3. 2011..More awareness of the association of CLL with these complications could facilitate earlier diagnosis and effective treatment...
- "Surgical" abdomen in a patient with chronic lymphocytic leukemia: a case of acquired angioedemaMoonjung Jung
Department of Medicine, The Methodist Hospital, Weill Cornell Medical College, 6550 Fannin Street, 1001, Houston, TX, 77030, USA
J Gastrointest Surg 15:2262-6. 2011..This disorder is strongly associated with chronic lymphocytic leukemia (CLL) and other indolent lymphoplasmacytic disorders...
- A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT StudySteven W Boyce
Washington Hospital Center, Washington, DC 20815 6048, USA
Am J Ther 18:14-22. 2011..The average medication cost per course of treatment was $1688 for desirudin and $8250 for argatroban. Desirudin warrants further study as a potentially cost-effective alternative to argatroban in patients with suspected HIT...
- Acute respiratory distress syndrome after rituximab infusionAlberto J Montero
Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX 77030, USA
Int J Hematol 82:324-6. 2005..ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion...
- P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cellsJianguo Wen
Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX, USA
Br J Haematol 140:169-80. 2008..These results suggest that ATO-induced p38 MAPK activation plays an important role in the resistance to ATO in myeloma cells and that p38 MAPK inhibition may overcome resistance to ATO treatment in myeloma patients...
- Pathologic quiz case: a 64-year-old man with hematuria, intracranial hemorrhage, and severe coagulation abnormalities. Long-acting warfarin-like rodenticide toxicityDax Kurbegov
Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine at The Methodist Hospital, Houston, Tex 77030, USA
Arch Pathol Lab Med 128:e181-2. 2004
- Limb amputation in hemoglobin SC disease after application of ice and elevationSadia Saleem
Hematology Oncology Section, Department of Medicine, Baylor College of Medicine, Houston, Texas
Am J Hematol 82:53-4. 2007..Vasoocclusion of the extremities to the point of gangrene is rarely reported in sickle cell disorders, and this case highlights the dangers of measures limiting blood flow in such patients...
- Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Clin Cancer Res 11:6916-23. 2005..Human interleukin-2 further potentiates the immunogenicity of human CD40 ligand in preclinical murine models...
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J Kuter
Massachusetts General Hospital, Boston, MA 02114, USA
Lancet 371:395-403. 2008..We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP...
- Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapyGustavo B F Oliveira
Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Durham, NC 27705, USA
Arch Intern Med 168:94-102. 2008..Despite widespread heparin use in clinical practice, the associated development of thrombocytopenia is an underrecognized and undertreated complication...
- Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After ThrombocytopenE Magnus Ohman
Division of Cardiology, Division of Hematology, and School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599 7075, USA
J Thromb Thrombolysis 19:11-9. 2005..IMPLICATIONS: The registry will provide valuable insights to the incidence and consequences of HIT and HITT that will enable improvements in diagnosis and treatment...
- Trousseau-like venous thromboemboli with benign ovarian tumorsNicolas R Cazap
Thromb Haemost 91:822-3. 2004